What the trial was testing
The BE RADIANT enrolled 743 patients with psoriasis. The study was sponsored by UCB Biopharma SRL and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
62% of patients on bimekizumab achieved clear skin with minimal quality of life impact at one year.
JAMA dermatology · 2026 · NCT03536884
These findings — that patients had no psoriasis visible and minimal impact on daily life at one year — were published in the JAMA dermatology and represent the headline result of the study.
Researchers tracked outcomes across 743 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with psoriasis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Bimekizumab is FDA-approved for plaque psoriasis. In this head-to-head comparison, it worked faster and better than secukinumab at relieving itching, skin pain, and scaling. Benefits lasted three years. Talk to your dermatologist about whether bimekizumab is right for you.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open psoriasis trials
Managing Psychological Distress Through Mindfulness-based CBT to Evaluate Its Effectiveness on Self-compassion Among Psoriasis Patients:The Mediating Role of Mental Health Locus of Control
Your research study is about evaluating the effectiveness of \*\*Mindfulness-Based Cognitive Therapy (MBCT)\*\* in reducing psychological distress among psoriasis patients and improving their self-compassion and Mental Health Locus of Control (MHLC). The study highlights that psoriasis patients often suffer not only from physical symptoms but also from psychological problems such as stress, anxiety, depression, self-judgment, and low self-compassion. Traditional treatments mainly focus on physical symptoms and may not fully address these emotional and psychological difficulties. To address this gap, the study proposes MBCT as a psychological intervention that combines mindfulness practices with cognitive therapy techniques. MBCT helps patients become more self-aware, reduce negative thinking, and develop self-compassion without self-judgment. The research also explores MHLC, which refers to how much control individuals believe they have over their health outcomes. The study aims to investigate whether MBCT can: * Reduce psychological distress, anxiety, depression, and stress levels * Improve self-compassion among psoriasis patients * Shift patients' locus of control from external to internal * Enhance emotional well-being and coping mechanisms The research follows a quantitative experimental design conducted in phases. Initially, baseline levels of distress, MHLC, and self-compassion will be assessed. Later, MBCT interventions will be implemented and evaluated for effectiveness. Overall, the study seeks to contribute to integrated psoriasis care by emphasizing the importance of psychological health alongside physical treatment, ultimately improving patients' quality of life and therapeutic outcomes.
Evaluation of Patient Satisfaction and Therapeutic Impact Regarding Joint Consultation Rheumatologist/Dermatologist
Current increase in the number of multidisciplinary consultations, but little documentation on their impact on patient management. More specifically, in the context of psoriatic arthritis, we are seeking to investigate the interest for the patient, through his or her satisfaction and the evolution of the activity of his or her pathology, of a global, joint management in Rheumatology and Dermatology.